Drug Trial Radar · NCT00575588
52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
Last checked: Nov 20, 2026Latest source record: Mar 21, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
891
Actual
Start
Dec 2007
Primary completion
Aug 2009
Study completion Aug 2010
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- Dec 18, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea in addition with metformin.
Conditions
- Type 2 Diabetes
Interventions
MetforminDrug
open-label metformin
SulphonylureaDrug
Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks)
SaxagliptinDrug
Saxagliptin 5 mg tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hemoglobin A1c (HbA1c) Change From Baseline to Week 52Time frame: Baseline to 52 Weeks
Locations
94 sites in 11 countries. Site status is shown where the registry gives one.
Research Site
Hanko, Finland
Research Site
Helsinki, Finland
Research Site
Kuopio, Finland
Research Site
Kuusankoski, Finland
Research Site
Mikkeli, Finland
Research Site
Oulu, Finland
Research Site
Tampere, Finland
Research Site
Aschaffenburg, Germany
Research Site
Berlin, Germany
Research Site
Dortmund, Germany
Research Site
Frankfurt, Germany
Research Site
Hamburg, Germany
Research Site
Hanover, Germany
Research Site
Mainz, Germany
Research Site
Mannheim, Germany
Research Site
Mülheim, Germany
Research Site
Pirna, Germany
Research Site
Ratzeburg, Germany
Research Site
Reinfeld, Germany
Research Site
Rhaunen, Germany
Research Site
Schmiedeberg, Germany
Research Site
Tübingen, Germany
Research Site
Wahlstedt, Germany
Research Site
Weinheim, Germany
Research Site
Balatonfüred, Hungary
Research Site
Békéscsaba, Hungary
Research Site
Budapest, Hungary
Research Site
Debrecen, Hungary
Research Site
Gyula, Hungary
Research Site
Kalocsa, Hungary
Research Site
Kaposvár, Hungary
Research Site
Kecskemét, Hungary
Research Site
Miskolc, Hungary
Research Site
Mosonmagyaróvár, Hungary
Research Site
Nyíregyháza, Hungary
Research Site
Székesfehérvár, Hungary
Research Site
Bangalore, Karnataka, India
Research Site
Indore, Madhya Pradesh, India
Research Site
Mumbai, Mashatra, India
Research Site
Jaipur, Rajasthan, India
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.